PCSK9 inhibitors are cholesterol-lowering medications. They work via the LDL receptors in the liver. These are a kind of "safety net" that removes LDL from your blood.
Normally, the protein PCSK9 causes some of these safety nets to be broken down. PCSK9 inhibitors block this process. As a result, more LDL receptors remain active in the liver. This allows your liver to remove more LDL from your blood , lowering your LDL cholesterol.
According to the American Heart Association, PCSK9 inhibitors (such as evolocumab and alirocumab) can often reduce LDL cholesterol by 50% or more . They are usually administered via injectiononce every 2 to 4 weeksand are expensive. You are usually only eligible for them if other cholesterol-lowering drugs are not effective enough and you are at high risk of cardiovascular disease.
Interested in the scientific history of PCSK9? In December 2025, a review article was published summarizing the most important steps and insights.
Share